Immunopathogenesis of severe acute respiratory syndromecoronavirus 2 (SARS-CoV-2) infection: a concise update

https://doi.org/10.19106/JMedSci005203202009

Shinta Trilaksmi Dewi(1*), Hardyanto Soebono(2)

(1) Department of Dermatology and Venereology, Faculty of Medicine, Public Health and Nursing, Universitas Gadjah Mada, Yogyakarta
(2) Department of Dermatology and Venereology, Faculty of Medicine, Public Health and Nursing, Universitas Gadjah Mada, Yogyakarta
(*) Corresponding Author

Abstract


Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a novel coronavirus which has been identified as the cause of the recently emerging coronavirus disease 2019 (COVID-19), a respiratory-related infectious disease, in late 2019. As of May 2020, SARS-CoV-2 has infected millions of people with almost 300.000 deaths worldwide only within few months since its first case was reported. While this infection mostly results in mild diseases, the increasing number of severe cases and deaths cannot be overlooked. Due to its novelty, many facets of SARS-CoV-2 pathogenesis are not well understood. This review presents updated knowledge on the key virus characteristics of SARS-CoV-2 and critical notes in the pathogenesis of this viral infection in human that is currently proposed to largely involve various aspects of the host immune responses. While the immediate impact of viral infection in the target cells contributes to the development of the disease, the ability of the virus to modify the host responses may result in the dysregulation of innate and adaptive immune responses, which commonly manifest in the severe spectrum of the disease. Having deep understanding on this complex process is central for tailoring appropriate management for the infected patients as well as for developing effective preventive measures, most importantly vaccine, which is hoped to occur in the near future.


Keywords


SARS-CoV-2; COVID-19; pathogenesis; ACE-2; immune response;

Full Text:

PDF


References

  1. Zhou P, Yang XL, Wang XG, Hu B, Zhang L, Zhang W, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 2020; 579(7798):270-3. https://doi.org/10.1038/s41586-020-2012-7
  2. WHO. Naming the coronavirus disease (COVID-19) and the virus that causes it. 2020. https://www.who.int/emergencies/diseases/novel-coronavirus-2019/technical-guidance/naming-the-coronavirus-disease-(covid-2019)-and-the-virus-that-causes-it (Accessed 12 May 12th, 2020).
  3. Kuiken T, Fouchier RA, Schutten M, Rimmelzwaan GF, van Amerongen G, van Riel D, et al. Newly discovered coronavirus as the primary cause of severe acute respiratory syndrome. Lancet 2003; 362(9380):263-70. ttps://doi.org/10.1016/S0140-6736(03)13967-0
  4. Zumla A, Hui DS, Perlman S. Middle East respiratory syndrome. Lancet 2015; 386(9997):995-1007. https://doi.org/10.1016/S0140-6736(15)60454-8
  5. Coronaviridae Study Group of the International Committee on Taxonomy of V. The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2. Nat Microbiol 2020; 5(4):536-44. https://doi.org/10.1038/s41564-020-0695-z
  6. Cui J, Li F, Shi ZL. Origin and evolution of pathogenic coronaviruses. Nat Rev Microbiol 2019; 17(3):181-92. https://doi.org/10.1038/s41579-018-0118-9
  7. Rabi FA, Al Zoubi MS, Kasasbeh GA, Salameh DM, Al-Nasser AD. SARS-CoV-2 and Coronavirus Disease 2019: What We Know So Far. Pathogens 2020; 9(3). https://doi.org/10.3390/pathogens9030231
  8. WHO. Coronavirus disease (COVID-19) outbreak situation. 2020. https://www.who.int/emergencies/diseases/novel-coronavirus-2019 (accessed 12 May 2020.
  9. Lan J, Ge J, Yu J, Shan S, Zhou H, Fan S, et al. Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor. Nature 2020; 581(7807):215-20. https://doi.org/10.1038/s41586-020-2180-5
  10. Jin Y, Yang H, Ji W, Wu W, Chen S, Zhang W, et al. Virology, Epidemiology, Pathogenesis, and Control of COVID-19. Viruses 2020;12(4). https://doi.org/10.3390/v12040372
  11. Cheng ZJ, Shan J. 2019 Novel coronavirus: where we are and what we know. Infection 2020; 48(2):155-63. https://doi.org/10.1007/s15010-020-01401-y
  12. Li X, Geng M, Peng Y, Meng L, Lu S. Molecular immune pathogenesis and diagnosis of COVID-19. J PharmAnal 2020; 10(2):102-8. https://doi.org/10.1016/j.jpha.2020.03.001
  13. Mousavizadeh L, Ghasemi S. Genotype and phenotype of COVID-19: Their roles in pathogenesis. J Microbiol Immunol Infect 2020. https://doi.org/10.1016/j.jmii.2020.03.022
  14. Wu A, Peng Y, Huang B, Ding X, Wang X, Niu P, et al. Genome composition and divergence of the novel coronavirus (2019-nCoV) originating in China. Cell Host Microbe 2020; 27(3):325-8. https://doi.org/10.1016/j.chom.2020.02.001
  15. Shereen MA, Khan S, Kazmi A, Bashir N, Siddique R. COVID-19 infection: Origin, transmission, and characteristics of human coronaviruses. J Adv Res 2020; 24:91-8. https://doi.org/10.1016/j.jare.2020.03.005
  16. Hoffmann M, Kleine-Weber H, Schroeder S, Kruger N, Herrler T, Erichsen S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell 2020; 181(2):271-80 e8. https://doi.org/10.1016/j.cell.2020.02.052
  17. Kuba K, Imai Y, Ohto-Nakanishi T, Penninger JM. Trilogy of ACE2: a peptidase in the renin-angiotensin system, a SARS receptor, and a partner for amino acid transporters. Pharmacol Ther 2010; 128(1):119-28. https://doi.org/10.1016/j.pharmthera.2010.06.003
  18. Song Z, Xu Y, Bao L, Zhang L, Yu P, Qu Y, et al. From SARS to MERS, thrusting coronaviruses into the spotlight. Viruses 2019;11(1). https://doi.org/10.3390/v11010059
  19. Zhang H, Penninger JM, Li Y, Zhong N, Slutsky AS. Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target. Intensive Care Med 2020; 46(4):586-90. https://doi.org/10.1007/s00134-020-05985-9
  20. Felsenstein S, Herbert JA, McNamara PS, Hedrich CM. COVID-19: Immunology and treatment options. Clin Immunol 2020; 215:108448. https://doi.org/10.1016/j.clim.2020.108448
  21. Li JY, You Z, Wang Q, Zhou ZJ, Qiu Y, Luo R, et al. The epidemic of 2019-novel-coronavirus (2019-nCoV) pneumonia and insights for emerging infectious diseases in the future. Microbes Infect 2020; 22(2):80-5. https://doi.org/10.1016/j.micinf.2020.02.002
  22. van Doremalen N, Bushmaker T, Morris DH, Holbrook MG, Gamble A, Williamson BN, et al. Aerosol and Surface Stability of SARS-CoV-2 as Compared with SARS-CoV-1. N Engl J Med 2020; 382(16):1564-7. https://doi.org/10.1056/NEJMc2004973
  23. Tang D, Comish P, Kang R. The hallmarks of COVID-19 disease. PLoS Pathog 2020; 16(5):e1008536. https://doi.org/10.1371/journal.ppat.1008536
  24. Prompetchara E, Ketloy C, Palaga T. Immune responses in COVID-19 and potential vaccines: Lessons learned from SARS and MERS epidemic. Asian Pac J Allergy Immunol 2020; 38(1):1-9.
  25. Vardhana SA, Wolchok JD. The many faces of the anti-COVID immune response. J Exp Med 2020; 217(6).e20200678. https://doi.org/10.1084/jem.20200678
  26. Jose RJ, Manuel A. COVID-19 cytokine storm: the interplay between inflammation and coagulation. Lancet Respir Med2020; 8(6):e46-e7. https://doi.org/10.1016/S2213-2600(20)30216-2
  27. Fu Y, Cheng Y, Wu Y. Understanding SARS-CoV-2-mediated inflammatory responses: from mechanisms to potential therapeutic tools. Virol Sin 2020;3:1-6. https://doi.org/10.1007/s12250-020-00207-4
  28. Ni L, Ye F, Cheng M-L, Feng Y, Deng Y-Q, Zhao H, et al. Detection of SARS-CoV-2-specific humoral and cellular immunity in COVID-19 convalescent individuals. Immunity 2020; 52(6):971–77.e3. https://doi.org/10.1016/j.immuni.2020.04.023
  29. Premkumar L, Segovia-Chumbez B, Jadi R, Martinez DR, Raut R, Markmann A, et al. The receptor binding domain of the viral spike protein is an immunodominant and highly specific target of antibodies in SARS-CoV-2 patients. Sci Immunol 2020; 5(48). https://doi.org/10.1126/sciimmunol.abc8413
  30. Thevarajan I, Nguyen THO, Koutsakos M, Druce J, Caly L, van de Sandt CE, et al. Breadth of concomitant immune responses prior to patient recovery: a case report of non-severe COVID-19. Nat Med 2020; 26(4):453-5. https://doi.org/10.1038/s41591-020-0819-2
  31. Iwasaki A, Yang Y. The potential danger of suboptimal antibody responses in COVID-19. Nat Rev Immunol 2020; 20(6):339-41. https://doi.org/10.1038/s41577-020-0321-6
  32. Weiskopf D, Schmitz KS, Raadsen MP, Grifoni A, Okba NMA, Endeman H, et al. Phenotype of SARS-CoV-2-specific T-cells in COVID-19 patients with acute respiratory distress syndrome. 2020. https://doi.org/10.1101/2020.04.11.20062349
  33. Xu Z, Shi L, Wang Y, Zhang J, Huang L, Zhang C, et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med 2020; 8(4):420-2. https://doi.org/10.1016/S2213-2600(20)30076-X
  34. Braun J, Loyal L, Frentsch M, Wendisch D, Georg P, Kurth F, et al. Presence of SARS-CoV-2-reactive T cells in COVID-19 patients and healthy donors. medRxiv 2020. https://doi.org/10.1101/2020.04.17.20061440
  35. Diao B, Wang C, Tan Y, Chen X, Liu Y, Ning L, et al. Reduction and functional exhaustion of T cells in patients with coronavirus disease 2019 (COVID-19). Front Immunol 2020; 11:827. https://doi.org/10.3389/fimmu.2020.00827



DOI: https://doi.org/10.19106/JMedSci005203202009

Article Metrics

Abstract views : 3150 | views : 2980


Bookmark and Share


Copyright (c) 2020 Shinta Trilaksmi Dewi, Hardyanto Soebono

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.